Geode Capital Management LLC boosted its holdings in FibroBiologics, Inc. (NASDAQ:FBLG - Free Report) by 90.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 599,760 shares of the company's stock after acquiring an additional 284,047 shares during the quarter. Geode Capital Management LLC owned about 1.71% of FibroBiologics worth $1,854,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. The Manufacturers Life Insurance Company acquired a new position in shares of FibroBiologics in the 3rd quarter worth $32,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of FibroBiologics in the 2nd quarter valued at $51,000. Jane Street Group LLC purchased a new position in FibroBiologics in the 3rd quarter worth about $37,000. Rhumbline Advisers acquired a new stake in FibroBiologics during the 2nd quarter worth about $115,000. Finally, Symphony Financial Ltd. Co. purchased a new stake in FibroBiologics during the third quarter valued at about $76,000.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $12.00 price target on shares of FibroBiologics in a report on Wednesday, November 13th. Maxim Group started coverage on shares of FibroBiologics in a research note on Tuesday, September 24th. They set a "buy" rating and a $12.00 target price on the stock. Rodman & Renshaw started coverage on FibroBiologics in a research report on Thursday, December 12th. They issued a "buy" rating and a $12.00 target price for the company. Finally, D. Boral Capital reissued a "buy" rating and set a $16.00 price target on shares of FibroBiologics in a research report on Friday, December 27th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $13.00.
View Our Latest Research Report on FibroBiologics
FibroBiologics Stock Down 8.8 %
FBLG stock traded down $0.20 during midday trading on Thursday, reaching $2.06. The company had a trading volume of 130,462 shares, compared to its average volume of 132,192. The company has a 50 day moving average of $2.52 and a two-hundred day moving average of $3.01. FibroBiologics, Inc. has a 1 year low of $1.08 and a 1 year high of $55.00.
About FibroBiologics
(
Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Recommended Stories
Before you consider FibroBiologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroBiologics wasn't on the list.
While FibroBiologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
